Loading...
OTCM
CMVLF
Market cap150mUSD
May 22, Last price  
1.25
Name

Cellectis SA

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.18%
Rev. gr., 5y
22.27%
Revenues
42m
+5,397.48%
4,101,36014,770,16417,319,04420,980,18320,728,40327,814,95422,816,15026,298,70155,043,40442,584,45125,188,00012,731,00015,190,00073,949,00073,949,00019,171,000755,00041,506,000
Net income
-37m
L-63.62%
0185,1490000024,32000-99,368,000-78,693,000-90,686,000-72,571,000-86,280,000-98,688,000-101,059,000-36,761,000
CFO
23m
P
01,779,1010000050,738,1193,537,9260-52,327,000-68,137,000-69,142,000-80,262,000-104,562,000-87,444,000-24,746,00022,989,000

Profile

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
URL
https://www.cellectis.com/
IPO date
Feb 06, 2007
Employees
231
Domiciled in
FR
Incorporated in
FR

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
41,506
5,397.48%
755
-96.06%
19,171
-74.08%
Cost of revenue
108,138
105,195
119,875
Unusual Expense (Income)
NOPBT
(66,632)
(104,440)
(100,704)
NOPBT Margin
Operating Taxes
(6,211)
87
Tax Rate
NOPAT
(66,632)
(98,229)
(100,791)
Net income
(36,761)
-63.62%
(101,059)
2.40%
(98,688)
14.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
82,822
67,936
(1,138)
BB yield
-51.21%
-38.69%
1.19%
Debt
Debt current
13,226
13,664
12,960
Long-term debt
120,865
122,842
127,119
Deferred revenue
Other long-term liabilities
8,007
22,881
2,391
Net debt
(133,736)
(75,162)
33,591
Cash flow
Cash from operating activities
22,989
(24,746)
(87,444)
CAPEX
(2,583)
(1,073)
(2,441)
Cash from investing activities
(102,808)
(15,510)
(2,761)
Cash from financing activities
89,113
82,865
1,145
FCF
(49,754)
(83,074)
(59,789)
Balance
Cash
260,306
203,815
97,697
Long term investments
7,521
7,853
8,791
Excess cash
265,752
211,630
105,529
Stockholders' equity
(363,255)
(438,091)
(457,181)
Invested Capital
593,756
630,723
665,304
ROIC
ROCE
EV
Common stock shares outstanding
89,852
57,013
45,547
Price
1.80
-41.56%
3.08
46.67%
2.10
-74.14%
Market cap
161,734
-7.90%
175,599
83.59%
95,649
-73.72%
EV
27,998
100,437
137,213
EBITDA
(46,786)
(85,917)
(82,269)
EV/EBITDA
Interest
7,453
6,428
3,787
Interest/NOPBT